Anti-Mouse/Human Interleukin-5 (IL-5) - PE
| Code | Size | Price |
|---|
| LEI-I-1064-25ug | 25 ug | £212.00 |
Quantity:
| LEI-I-1064-100ug | 100 ug | £409.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG1 κ
Antibody Clonality: Monoclonal
Antibody Clone: TRFK5
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Flow Cytometry
- Immunocytochemistry (ICC)
Shipping:
2-8°C
Storage:
This R-PE conjugated antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
Mast cells, T cells, eosinophils
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Partially-purified T cell clone supernatant
Long Description:
IL-5 is a 26 kD TH2 cytokine and a homodimeric glycoprotein that is part of the hematopoietic family. IL-5 stimulates B cell growth as well as increases Ig secretion. It is the main factor that promotes the terminal differentiation of eosinophil progenitors and enhances the effector capacity of mature eosinophils. IL-5 is a major regulator of eosinophil accumulation in tissues. In fact, in Hodgkin lymphoma, the characteristically observed eosinophilia is suspected to result from an increased production of IL-5. IL-5 may also be the cause of several allergic diseases including asthma, where it is thought that eosinophils have a significant role in the disease pathology. There are several mAbs currently in use that target IL-5 for the treatment of severe eosinophilic asthma.
NCBI Gene:
161913567
Target:
IL-5
Related Products
| Product Name | Product Code | Supplier | Anti-Mouse/Human IL-5 - Purified in vivo PLATINUM™ Functional Grade (DISCONTINUED) | LEI-I-1192 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|